228 related articles for article (PubMed ID: 26970288)
21. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.
Brown ML; Riley GF; Potosky AL; Etzioni RD
Med Care; 1999 Dec; 37(12):1249-59. PubMed ID: 10599606
[TBL] [Abstract][Full Text] [Related]
22. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Cogle CR; Craig BM; Rollison DE; List AF
Blood; 2011 Jun; 117(26):7121-5. PubMed ID: 21531980
[TBL] [Abstract][Full Text] [Related]
23. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective.
Kühne F; Mittendorf T; Germing U; Tesch H; Weinberg R; Grabenhorst U; Mohr A; Lipp R; von der Schulenburg JM
Ann Hematol; 2010 Dec; 89(12):1239-47. PubMed ID: 20574731
[TBL] [Abstract][Full Text] [Related]
24. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
25. Therapy-related myelodysplastic syndrome following primary breast cancer.
Malmgren JA; Calip GS; Pyott SM; Atwood MK; Kaplan HG
Leuk Res; 2016 Aug; 47():178-84. PubMed ID: 27414978
[TBL] [Abstract][Full Text] [Related]
26. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
27. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662
[TBL] [Abstract][Full Text] [Related]
28. Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates.
Durairaj S; Chew S; Hyslop A; Keenan N; Groves MJ; Tauro S
Am J Hematol; 2011 May; 86(5):406-10. PubMed ID: 21523799
[TBL] [Abstract][Full Text] [Related]
29. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population.
Komrokji RS; Matacia-Murphy GM; Al Ali NH; Beg MS; Safa MM; Rollison DE; List AF
Leuk Res; 2010 Jan; 34(1):59-62. PubMed ID: 19368972
[TBL] [Abstract][Full Text] [Related]
30. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
[TBL] [Abstract][Full Text] [Related]
31. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
Davidoff AJ; Hu X; Bewersdorf JP; Wang R; Podoltsev NA; Huntington SF; Gore SD; Ma X; Zeidan AM
Leuk Lymphoma; 2020 May; 61(5):1178-1187. PubMed ID: 31878809
[TBL] [Abstract][Full Text] [Related]
32. Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.
Adrianzen-Herrera D; Sparks AD; Singh R; Alejos-Castillo D; Batra A; Glushakow-Smith S; Pradhan K; Shastri A; Zakai NA
Blood Adv; 2023 Nov; 7(22):6913-6922. PubMed ID: 37729616
[TBL] [Abstract][Full Text] [Related]
33. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
34. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
35. Leukemia as a cause of death among patients with myelodysplastic syndromes (MDS) in a population- based cancer registry: improving estimates of MDS-related mortality in the population.
Polednak AP; Phillips C
J Registry Manag; 2012; 39(3):115-20. PubMed ID: 23443455
[TBL] [Abstract][Full Text] [Related]
36. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
37. Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013.
Al-Kali A; Zblewski D; Foran JM; Patnaik MS; Larrabee BR; Gangat N; Begna KH; Elliott MA; Hogan WJ; Tefferi A; Litzow MR; Go RS
Mayo Clin Proc; 2019 Aug; 94(8):1467-1474. PubMed ID: 31378228
[TBL] [Abstract][Full Text] [Related]
38. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
[TBL] [Abstract][Full Text] [Related]
39. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.
Zeidan AM; Zhu W; Stahl M; Wang R; Huntington SF; Giri S; Podoltsev NA; Gore SD; Ma X; Davidoff AJ
Leuk Lymphoma; 2019 Dec; 60(13):3181-3187. PubMed ID: 31170846
[TBL] [Abstract][Full Text] [Related]
40. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
